Artiva Biotherapeutics (NASDAQ:ARTV) Stock Rating Lowered by Wall Street Zen

Key Points

• Wall Street Zen downgraded Artiva Biotherapeutics (NASDAQ:ARTV) from "hold" to "sell," while Weiss Ratings also reaffirmed a sell and Needham maintained a buy with an $18 target.
• Analyst sentiment is mixed—one Strong Buy, three Buy and one Sell—resulting in a MarketBeat average rating of "Moderate Buy" and an average price target of $18.67.
• The stock opened at $6.81 with a market cap of $168.34M and a 52‑week range of $1.47–$7.75; Artiva reported quarterly EPS of ($0.84) (slightly beating estimates) and analysts forecast about ($4.95) EPS for the year.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued on Sunday.

Other research analysts have also recently issued research reports about the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Artiva Biotherapeutics in a research report on Tuesday, January 27th. Needham & Company LLC reaffirmed a "buy" rating and set a $18.00 target price on shares of Artiva Biotherapeutics in a research report on Wednesday, March 11th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $18.67.

Artiva Biotherapeutics Stock Performance

Shares of NASDAQ ARTV opened at $6.81 on Friday. The stock has a market capitalization of $168.34 million, a P/E ratio of -1.99 and a beta of 1.46. Artiva Biotherapeutics has a 52 week low of $1.47 and a 52 week high of $7.75. The stock's fifty day moving average is $5.37 and its 200 day moving average is $4.42.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last released its quarterly earnings data on Tuesday, March 10th. The company reported ($0.84) EPS for the quarter, beating the consensus estimate of ($0.87) by $0.03. Equities research analysts forecast that Artiva Biotherapeutics will post -4.95 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Bank of America Corp DE boosted its position in Artiva Biotherapeutics by 225.8% in the third quarter. Bank of America Corp DE now owns 16,145 shares of the company's stock worth $46,000 after purchasing an additional 11,190 shares during the last quarter. Prelude Capital Management LLC purchased a new position in Artiva Biotherapeutics in the third quarter worth $41,000. OMERS ADMINISTRATION Corp purchased a new position in Artiva Biotherapeutics in the fourth quarter worth $91,000. Bridgeway Capital Management LLC purchased a new position in Artiva Biotherapeutics in the second quarter worth $53,000. Finally, Renaissance Technologies LLC boosted its position in Artiva Biotherapeutics by 46.8% in the fourth quarter. Renaissance Technologies LLC now owns 116,200 shares of the company's stock worth $498,000 after purchasing an additional 37,053 shares during the last quarter.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company's proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva's pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.